A giant limulid trackway (Kouphichnium lithographicum) from the lithographic limestones of Cerin (Late Kimmeridgian, France) : ethological and environmental implications

International audienceA well-preserved large limulid trackway related to Kouphichnium lithographicum is described from the Upper Kimmeridgian Lithographic Limestones of Cerin (Ain, France). It is three meters long and exhibits ten successive sets of imprints characterized by a pair of well-preserved tetradactyl external imprints of legs VI (named pushers) and a variable number (mostly three pairs) of straight thin intermediate imprints (legs III-V). The trackway is unusually wide and was probably made by a very large adult approximately 38 cm wide and 80 cm long when related to the proportions of the modern Limulus polyphemus. The straightness of the trackway, the great repeat distance (stride), the length of series of leg imprints, their slight angle to the mid-line, the well-marked pusher (= leg VI) imprints and the absence of groove made by the telson all indicate fast progression of a vigorous animal on the sea-floor. This walking trackway can be easily differentiated from other limulid crawling, ploughing, and dying trackways usually found in lithographic limestones or other deposits of the geological record. Main characteristics of these different limulid trackways are evidenced. The occurrence of a living adult in the Cerin restricted lagoon is probably related to a brief period of connection with the open sea. This occurrence indicates either a passive introduction of the animal into the lagoon or a spawning behaviour

mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes

Immunization with mRNA encoding tumor antigen is an emerging vaccine strategy for cancer. In this paper, we demonstrate that mice receiving systemic injections of MART1 mRNA histidylated lipopolyplexes were specifically and significantly protected against B16F10 melanoma tumor progression. The originality of this work concerns the use of a new tumor antigen mRNA formulation as vaccine, which allows an efficient protection against the growth of a highly aggressive tumor model after its delivery by intravenous route. Synthetic melanoma-associated antigen MART1 mRNA was formulated with a polyethylene glycol (PEG)ylated derivative of histidylated polylysine and L-histidine-(N,N-di-n-hexadecylamine)ethylamide liposomes (termed histidylated lipopolyplexes). Lipopolyplexes comprised mRNA/polymer complexes encapsulated by liposomes. The tumor protective effect was induced with MART1 mRNA carrying a poly(A) tail length of 100 adenosines at an optimal dose of 12.5 microg per mouse. MART1 mRNA lipopolyplexes elicited a cellular immune response characterized by the production of interferon-gamma and the induction of cytotoxic T lymphocytes. Finally, the anti-B16 response was enhanced using a formulation containing both MART1 mRNA and MART1-LAMP1 mRNA encoding the antigen targeted to the major histocompatibility complex class II compartments by the lysosomal sorting signal of LAMP1 protein. Our results provide a basis for the development of mRNA histidylated lipopolyplexes for cancer vaccine

How to Succeed in Marketing Marine Natural Products for Nutraceutical, Pharmaceutical and Cosmeceutical Markets

The marine ecosystem shelters a vast number of macro- and microorganisms that have developed unique metabolic skills to survive in diverse and hostile habitats. These survival strategies often result in the biosynthesis of an array of secondary metabolites with specific activities and functions in the cellular context. Several metabolites can give origin to high-value commercial products for nutraceutical, pharmaceutical and cosmeceutical markets, among others. This chapter outlines those industries’ paths for marketing marine natural products (MNPs), from discovery and development up to final product marketing. Focus is given on compounds that successfully reached the market and, particularly, the approaches employed by the nutraceutical, pharmaceutical and cosmeceutical companies that succeeded in marketing those products. Some key failures in each market segment are analysed, allowing lessons to be learned and key hurdles to be avoided in MNP development. The main challenges faced during MNP programs are assessed and mapped in the market funnel of common product development routes. Suggestions to surpass these challenges are provided, in order to improve market entry success rates of highly promising marine bioactives in current pipelines, highlighting what can be applied to novel and/or ongoing MNP development programs.info:eu-repo/semantics/publishedVersio